EU/3/19/2199: Orphan designation for the treatment of glioma

Veledimex

Overview

On 21 August 2019, orphan designation EU/3/19/2199 was granted by the European Commission to Ziopharm Oncology Limited, Ireland, for veledimex for the treatment of glioma.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2022 on request of the Sponsor.

Key facts

Active substance
Veledimex
Intended use
Treatment of glioma
Orphan designation status
Withdrawn
EU designation number
EU/3/19/2199
Date of designation
21/08/2019
Sponsor

Ziopharm Oncology Limited
1 Castlewood Avenue
Rathmines
Dublin 6 D06 H685
Co. Dublin
Ireland
Tel: +353 1 4970935
E-mail: infoeu@ziopharm.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating